Register for OBR daily

Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CBMG $33.00 6.8299 +26.10%
Kite $23.53 1.5100 +6.86%
EXEL $4.40 0.2100 +5.01%
PCYC $108.50 3.6800 +3.51%
CLSN $3.47 0.0800 +2.36%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CERU $4.28 -0.5200 -10.83%
TGTX $7.91 -0.5300 -6.28%
INO $11.90 -0.7300 -5.78%
ECYT $5.96 -0.3400 -5.40%
GALT $14.54 -0.7800 -5.09%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Cancer Cells May Guide Treatment

(Boston Globe) July 11, 2014 - A Boston-based team published proof Thursday that one of the most alluring ideas in cancer care can work: Exceedingly rare tumor cells can be filtered from a patient’s blood sample and used to noninvasively monitor the evolution of cancer and identify the most promising treatments.
read article (free registration required) 

Doctor Quits Uterine-Device Safety Panel Over Conflict

(Wall Street Journal) July 10, 2014 - A member of a panel advising the government on the safety of a medical device that can spread cancer in women stepped down after the U.S. Food and Drug Administration reviewed consulting fees he accepted from a device manufacturer, the agency said Thursday.
read article (paid subscription required) 

Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade)/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma

(Yahoo! Finance) July 9, 2014 - Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone ("TBorD") in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.
read article 

14 Insanely Important Biotech/Drug Trading Catalysts For the Rest of 2014

(TheStreet) July 10, 2014 - Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
read article 

Health Insurers Are Trying New Payment Models, Study Shows

(New York Times) July 9, 2014 - The sector is spending more than $65 billion a year in new “value-based” payment models, according to a Blue Cross Blue Shield Association study, which looked at 350 programs.
read article 

Celgene's Otezla Misses Mark in Ph III Arthritis Study

(PharmaTimes [UK]) July 9, 2014 - Celgene's psoriatic arthritis drug Otezla (apremilast) has failed to hit targets in a late-stage trial assessing its potential in ankylosing spondylitis, a form of arthritis that affects the spine.
read article 

In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis

(New York Times) July 9, 2014 - An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it.
read article 

Sarepta Data Disappoints Wall Street as Expert Sees a Sea Change at FDA

(Forbes) July 10, 2014 - It may be one of the most-watched small studies in biotech history. This morning, Sarepta Therapeutics of Cambridge, Mass., released 144-week data from its study of eteplirsen, for Duchenne muscular dystrophy, in 12 boys.
read article 

The Cancer Tests You Really Need—And Those You Don't

(Consumer Reports) July 9, 2014 – Consumer Reports advice on mammograms, Pap tests, colonoscopy, and the PSA test.
read article 

USC's Keck Medicine Joins Trend to Combine Academic and Local Cancer Care

( July 9, 2014 - Keck Medicine of the University of Southern California completed its acquisition of Orange Coast Oncology Hematology Medical Associates in a move intended to extend the academic medical center's comprehensive cancer care to more convenient local settings.
read article 

Penn Mesothelioma Program Receives $8 Million NCI Grant to Study Effects of Photodynamic Therapy Plus Surgery on Patient Survival and Disease Progression

(Penn Medicine) July 10, 2014 - Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer Institute to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare, aggressive and deadly cancer that most often manifests itself in the lining of the lungs and is caused almost exclusively by exposure to asbestos.
read press release 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostic Test For Cancer Treatment

(Ventana) July 10, 2014 - Ventana Medical Systems, Inc., a member of the Roche Group, today announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays.
read corporate press release 

MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code For the MelaFind System

(StreetInsider) July 10, 2014 - MELA Sciences, Inc., announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind system as an aid in the detection of melanoma.
read article 

Basilea's Partner Astellas Submits Isavuconazole U.S. NDA For the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

(MarketWatch) July 9, 2014 - Basilea Pharmaceutica Ltd. reports today that its co-development partner Astellas Pharma Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (zygomycosis).
read article 

Fox Chase Cancer Center Researchers Recommend Updating the ‘Staging Criteria’ for Breast Cancer Diagnoses

(Fox Chase) July 7, 2014 - New findings from Fox Chase Cancer Center paint a relatively optimistic picture of women’s chances of surviving a subset of breast cancers that have spread to the chest wall or skin, but not beyond.
read press release 

Pancreatic Surgery Complications Impact Hospital Costs More Than Length of Stay

(UC Davis CCC) July 10, 2014 - When it comes to a specific type of pancreatic surgery, post-operative complications have a far greater impact on total cost than does how long the patient stays in the hospital, according to a published paper by UC Davis researchers.
read press release 

Largest Study of Consolidation Therapy For Ewing's Sarcoma

(Medscape Medical News) July 9, 2014 - As consolidation therapy for Ewing's sarcoma, there is little difference in the cure rate between cyclophosphamide and ifosfamide, new research shows.
read article (free registration required) 

New Target For Aggressive Bladder Cancer

(Cancer Research UK/Press Association) July 9, 2014 - An international team of scientists have discovered a faulty process in certain bladder cancers that could point to new ways to treat patients with an aggressive form of the disease.
read article 

Depressed Men With Prostate Cancer Fare Worse

(Doctors Lounge/HealthDay News) July 9, 2014 - Depressed men with a diagnosis of intermediate- or high-risk prostate cancer have worse overall outcomes, according to a study published online July 7 in the Journal of Clinical Oncology.
read article 

Vasectomy and Prostate Ca: How Serious the Link?

(MedPage Today) July 9, 2014 - Men who had a vasectomy had a significantly greater risk of developing aggressive, potentially fatal prostate cancer, according to data from a 50,000-patient cohort study.
read article (free registration required) 

Cancer Drug Finds New Use as Fertility Treatment

(USA Today) July 9, 2014 - New treatment regiment boosts pregnancy rates in women with common condition.
read article 

Breast Cancer Drug Aromasin May Be Option for Some Premenopausal Women

(U.S. News & World Report/HealthDay News) July 9, 2014 - The drug exemestane worked slightly better than the drug tamoxifen at preventing a recurrence of breast cancer in certain premenopausal women, according to a new study.
read article 

Study Identifies Novel Genomic Changes in the Most Common Type of Lung Cancer

(NIH) July 9, 2014 - Researchers from The Cancer Genome Atlas (TCGA) Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer.
read press release 

Bristol to Seek Melanoma Approval For Opdivo Ahead of Expectations

(Reuters) July 10, 2014 - Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected.
read article 

Lung Cancer Genomic Mapping Yields New Targets in Study

(Bloomberg) July 9, 2014 - Mutations within a small cluster of genes tied to tumor growth are involved in three-quarters of the cases of the most common form of lung cancer, according to a study that could help link treatment to specific genetic flaws.
read article